Form 4: Enanta Pharmaceuticals CEO Jay R. Luly Reports Stock Transaction

Enanta Pharmaceuticals CEO Jay R. Luly forfeited 3,829 shares of common stock to cover withholding taxes related to the settlement of restricted stock units.

Summary

• Jay R. Luly, the President and CEO of Enanta Pharmaceuticals, reported a transaction involving the company's common stock.
• On December 1, 2024, Mr. Luly forfeited 3,829 shares of common stock.
• The shares were forfeited to cover withholding taxes due from the settlement of restricted stock unit awards.
• The restricted stock units were granted on November 20, 2020, and November 19, 2021.
• Following the transaction, Mr. Luly beneficially owns 806,780 shares of Enanta Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is neither positive nor negative for the company's overall performance. It is a neutral event.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies.

Comparison to Industry Standards

• Stock forfeitures to cover tax obligations are a standard practice in executive compensation across the pharmaceutical industry.
• Many companies use restricted stock units as part of their compensation packages, and the tax implications are typically handled through similar forfeiture mechanisms.
• This transaction is similar to those seen at companies like Gilead Sciences and Vertex Pharmaceuticals, where executives regularly report stock transactions related to equity awards.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a standard part of executive compensation.
• The forfeiture of shares does not dilute the existing shares as it is a return of shares to the company.

Key Dates

Keywords

Enanta Pharmaceuticals, stock transaction, Form 4, insider trading, Jay R. Luly, restricted stock units, withholding taxes, executive compensation